

Notice: Collaboration Agreement with Sumitomo Dainippon Pharma Co, Ltd.

Luxna Biotech Co., Ltd. (Osaka, President & CEO Hideaki Sato, hereinafter referred to as “Luxna Biotech”) and Sumitomo Dainippon Pharma Co., Ltd. (Osaka, Representative Director, President & CEO Hiroshi Nomura, hereinafter referred to as “Sumitomo Dainippon Pharma”) have concluded a collaboration agreement as follows:

- The Reason for Collaboration Agreement

Sumitomo Dainippon Pharma has accumulated wealth of knowledge based on their achievement of drug discovery research in the area of psychiatry and neurology disorders, while Luxna Biotech has accumulated drug discovery technology for oligonucleotides therapeutics based on our bridged nucleic acids technology. By combing those technologies, we have reached an agreement to create oligonucleotide therapeutics for multiple intractable neurological diseases which target specific genes.

- Contents of Collaboration Agreement

Luxna Biotech and Sumitomo Dainippon Pharma have started our collaboration to create an antisense oligonucleotide therapeutics in the field of neurological diseases caused by gene mutations since June 2019. On this occasion, we have agreed to expand the target disease and gene.

(Remarks)

About Oligonucleotides Therapeutics

Oligonucleotides Therapeutics are linear modified nucleic acid chains that work as active pharmaceutical ingredients against a disease-related target gene by controlling protein expression. It is particularly the focus of attention in recent years due to their high specificity and potency against target molecules compared to small molecule drugs or antibody drugs. Also, scaling up for GMP manufacture is more feasible than that of biologic therapeutics from the healthcare economic perspectives.

About Luxna Biotech Co., Ltd.

Luxna Biotech was founded to support patients who are suffering from diseases and to create oligonucleotide therapeutics by installing technologies that promote the use of oligonucleotide therapeutics in the clinical setting.

About Sumitomo Dainippon Pharma Co., Ltd.

Sumitomo Dainippon Pharma defines its corporate mission as "to broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide". Sumitomo Dainippon Pharma's goal is to create innovative pharmaceutical products in the focus research areas with high unmet medical needs of Psychiatry & Neurology, Oncology and

Regenerative Medicine/Cell Therapy.

Contact information

Management Division, Luxna Biotech Co., Ltd.

E-mail: info@luxnabiotech.co.jp

HP: <https://luxnabiotech.co.jp/en/>

EOD